Oxford BioMedica plc (OXB.L)
| Previous close | 428.00 |
| Open | 411.95 |
| Bid | 408.50 x 0 |
| Ask | 440.00 x 0 |
| Day's range | 411.95 - 431.96 |
| 52-week range | 276.62 - 907.00 |
| Volume | |
| Avg. volume | 132,126 |
| Market cap | 406.716M |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | 21.12 |
| EPS (TTM) | 0.20 |
| Earnings date | 18 Apr 2023 - 24 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,070.29 |
- Simply Wall St.
A Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)
How far off is Oxford Biomedica plc ( LON:OXB ) from its intrinsic value? Using the most recent financial data, we'll...
- Globe Newswire
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer Oxford, UK – 22
- Globe Newswire
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces exchange of contracts for the sale of its Windrush Court facility (the "Property") to Kadans Science Partner (“Kadans”) for £60 million. Completion is due to occur on or around the 18th November 2022. The sale proceeds of £60 million exceed the target o
